Short answer
Amgen (AMGN) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 unaudited results, plus September 30 financial position, announced November 3, 2026.
Amgen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 unaudited results, plus September 30 financial position, announced November 3, 2026
- Exhibit 99.1 contains the earnings release with GAAP results and non-GAAP reconciliations
- Key adjusted metrics include EPS, operating income, operating margin, tax rate, operating expenses and free cash flow
- Non-GAAP adjustments primarily exclude acquisition-related charges, restructuring costs and selected investment, legal and contingent-consideration items
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $10.4B, up 8%, with product sales up 8% on volume growth and 17 products posting double-digit growth
- GAAP EPS $7.08, up 19%, while operating margin expanded 9.9 points to 37.5%
- Non-GAAP EPS $6.45, up 14%, with non-GAAP margin reaching 47.3%
- Growth concentrated in Repatha $1.085B, UPLIZNA $451M, TEZSPIRE $538M and IMDELLTRA $406M
- Biosimilar erosion intensified: Prolia sales fell 45% to $632M and XGEVA fell 47% to $288M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amgen 8-K filings
Get the next AMGN 8-K as it lands
Follow AMGN for push alerts, or ask the research agent what this filing means.